Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
2016-002411-17Phase 2Completed
- Sponsor
- UCB
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Rozanolixizumab with Placebo (2 arms). Primary endpoint: Change in iRODS score from Baseline to Week 13. Started Feb 2019; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2016-002411-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002411-17.